December 2021 Vol 12, No 12
Caring for Sexual and Gender Minority Patients: What Factors Explain Self- Reported Competence Among Healthcare Professional Students?
Lesbian, gay, bisexual, transgender, queer, and intersex (LGBTQI) people—broadly included within the umbrella of “sexual and gender minorities” (SGM)—have unique health and healthcare needs. SGM youth experience higher rates of family rejection, increased use of tobacco and other substances, more bullying, and higher suicide rates.
Patient-Reported Outcomes from the Phase 3, Randomized Study of Acalabrutinib with or without Obinutuzumab versus Chlorambucil plus Obinutuzumab for Treatment-Naive Chronic Lymphocytic Leukemia (ELEVATE-TN)
P Walker , JP Sharman, W Jurczak, T Munir, V Banerji, S Coutre, JA Woyach, G Salles, WG Wierda, P Patel, MH Wang, U Emeribe, E Flood, JC Byrd, P Ghia
Impact of Age on Efficacy and Safety of Relugolix: A Subgroup Analysis from the Randomized, Phase 3 HERO Study versus Leuprolide in Men with Advanced Prostate Cancer
Michael S. Cookson, MD, MMHC, Neal D. Shore, MD, Daniel J. George, MD, Hideyuki Akaza, MD, Daniel R. Saltzstein, MD, Ronald Tutrone, MD, Alberto Bossi, MD, Bruce Brown, MD, Bryan Selby, MS, Sophia Lu, PhD, Jackie Walling, MBChB, PhD, Bertrand Tombal, MD, PhD, Fred Saad, MD
Tomasz M. Beer, Charles H. McDonnell, III, Lincoln Nadauld, Minetta C. Liu, Eric A. Klein, Robert Reid, Catherine R. Marinac, Karen C. Chung, Margarita Lopatin, Eric T. Fung, Deborah Schrag
Characterization of Adverse Reactions in Patients with Advanced Endometrial Cancer (aEC) Receiving Lenvatinib + Pembrolizumab (Study 309/KEYNOTE-775): Nurse Roles in Patient Education and Adverse-Reaction Management
Here we are at the end of another rather unusual year. As the pandemic continues, we’ve had to adapt our oncology practices, our personal lives, and our professional organizations to function in the safest way possible.
Results from the Final Analysis of the Phase 3 iNNOVATE Study: Nursing Experience with Patients Receiving Ibrutinib plus Rituximab for Waldenström’s Macroglobulinemia
Kate Mimken, NP-C, Tolu Adewuya, MMedSci, PhD, CCRC, Bernhard Hauns, MD, PhD, Israel Arango-Hisijara, MD, Leonard T. Heffner, MD, Jeffrey V. Matous, MD
Results 1 - 17 of 17